Haloperidol decanoate Injection 50mg/mL, packaged in a) 1 mL Single-Dose Vials (NDC 70069-381-01)...
FDA Drug Recall #D-0506-2024 — Class II — April 24, 2024
Recall Summary
| Recall Number | D-0506-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 24, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | SOMERSET THERAPEUTICS LLC |
| Location | Somerset, NJ |
| Product Type | Drugs |
| Quantity | 5,578 units |
Product Description
Haloperidol decanoate Injection 50mg/mL, packaged in a) 1 mL Single-Dose Vials (NDC 70069-381-01) and b) 10 1mL Single-Dose Vials (NDC 70069-381-10), Rx only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India.
Reason for Recall
Presence of Foreign Substance: This oil based product may contain trace amounts of water for injection (WFI).
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot #: a) A230412A, Exp. Date 07/2025; b)A230412B, Exp. Date 07/2025
Other Recalls from SOMERSET THERAPEUTICS LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0398-2026 | Class II | Dexamethasone Sodium Phosphate Injection, USP, ... | Feb 4, 2026 |
| D-0238-2026 | Class III | Cisatracurium Besylate Injection USP, 20 mg/10 ... | Nov 26, 2025 |
| D-0237-2026 | Class III | Cisatracurium Besylate Injection USP, 200mg/20m... | Nov 26, 2025 |
| D-0236-2026 | Class III | Cisatracurium Besylate Injection USP, 10 mg/5 m... | Nov 26, 2025 |
| D-0169-2025 | Class III | Atropine Sulfate Ophthalmic Solution, USP 1%, 5... | Dec 16, 2024 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.